PAI Antibodies

Santa Cruz Biotechnology features a diverse variety of PAI Antibodies for advanced research in the field of protease inhibition. PAI Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Plasminogen activator inhibitor (PAI) plays a crucial role in regulating fibrinolysis by inhibiting tissue-type and urokinase-type plasminogen activators. This regulation is vital for maintaining hemostasis and preventing excessive bleeding, making PAI an important target in studies related to cardiovascular diseases, cancer, and other pathological conditions. Understanding the function and regulation of PAI can provide insights into therapeutic strategies for various disorders. PAI research has revealed significant implications in wound healing, tissue remodeling, and vascular development. Ongoing studies continue to uncover new roles of PAI in cellular signaling pathways and disease progression. Recent findings highlight PAI's involvement in inflammatory responses and metabolic regulation. Santa Cruz Biotechnology monoclonal antibodies for PAI research support scientists worldwide in advancing our understanding of disease mechanisms and potential therapeutic approaches.